Published in Oncology on February 01, 2000
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. Br J Cancer (2010) 0.96
The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur J Nutr (2004) 0.94
High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cells. Br J Cancer (2001) 0.87
Sunscreen use and duration of sun exposure: a double-blind, randomized trial. J Natl Cancer Inst (1999) 3.75
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med (1999) 1.67
Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. Br J Surg (2010) 1.65
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg (1996) 1.54
Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods (2000) 1.53
Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J Immunother (2000) 1.52
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Adjuvant interferon-alpha for melanoma revisited: news from old and new studies. Ann Oncol (2001) 1.43
Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol (1993) 1.39
[Thyroid metastases as cause of thyroid swelling]. Ned Tijdschr Geneeskd (1993) 1.38
The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group. Ann Oncol (2001) 1.38
Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery (1994) 1.23
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20
Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest (1998) 1.19
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst (1995) 1.15
Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery (1987) 1.15
Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer (2000) 1.14
Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources. Int J Cancer (1996) 1.13
Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer. Br J Surg (1999) 1.13
Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer (1999) 1.06
TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer (2000) 1.04
Stromal influences on breast cancer cell growth. Br J Cancer (1992) 1.03
Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer (2000) 1.01
Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg (1996) 1.00
Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer (1996) 0.99
VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol (1995) 0.98
The microscopic anatomy of experimental rat CC531 colon tumour metastases: consequences for immunotherapy? Clin Exp Metastasis (2000) 0.97
Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am (1997) 0.96
Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg (1995) 0.96
Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer Suppl (1992) 0.94
Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. Br J Cancer (1997) 0.93
Ultrasound-guided percutaneous transhepatic cholecystostomy for acute acalculous cholecystitis. Arch Surg (1985) 0.91
Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res (1998) 0.91
Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures. FEBS Lett (1998) 0.91
Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol (1996) 0.90
Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg (1999) 0.90
Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol (1999) 0.89
Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res (1999) 0.89
Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. Ann Surg (1998) 0.88
High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer. J Immunother (1997) 0.87
The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma. Clin Exp Metastasis (2000) 0.86
Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res (1994) 0.86
Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg (1994) 0.85
Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg (1999) 0.85
Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats. Hum Gene Ther (2001) 0.85
A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer (1995) 0.85
Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. Eur J Surg Oncol (2001) 0.84
Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg (1994) 0.83
Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol (2000) 0.83
Systemic leakage during isolated limb perfusion for melanoma. Br J Surg (1993) 0.83
Biodistribution of lymphokine-activated killer (LAK) cells in Wag rats after hepatic-artery or jugular-vein infusion. Int J Cancer (1992) 0.83
Controlled introduction of the sentinel node biopsy in breast cancer in a multi-centre setting: the role of a coordinator for quality control. Eur J Surg Oncol (2000) 0.82
A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. Br J Cancer (1990) 0.82
The regulatory role of CD45 on rat NK cells in target cell lysis. J Immunol (1999) 0.82
Effects of the interferon-inducer ABPP on colon cancer in rats; importance of tumor load and tumor site. Cancer Immunol Immunother (1986) 0.82
Transient induction of E-selectin expression following TNF alpha-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific. J Immunother Emphasis Tumor Immunol (1996) 0.82
Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol (1998) 0.82
Effects of isolated limb perfusion with tumour necrosis factor-alpha on the function of monocytes and T lymphocytes in patients with cancer. Eur J Clin Invest (1996) 0.82
Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats. J Surg Res (1998) 0.81
Transforming growth factor beta secretion from primary breast cancer fibroblasts. Mol Cell Endocrinol (1995) 0.80
TNF-alpha has no direct in vivo metabolic effect on human muscle. Int J Cancer (1997) 0.80
Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am J Pathol (1998) 0.80
Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs? Melanoma Res (1994) 0.80
Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur J Cancer (1993) 0.80
Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br J Cancer (2000) 0.80
Rat interleukin-2-activated natural killer (A-NK) cell-mediated lysis is determined by the presence of CD18 on A-NK cells and the absence of major histocompatibility complex class I on target cells. Eur J Immunol (1994) 0.80
The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells. Cancer (1987) 0.80
Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas. Ann Surg (2000) 0.80
TNF is here to stay--revisited. Trends Immunol (2001) 0.79
Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer (1995) 0.79
Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion. Br J Cancer (1997) 0.79
In vivo model systems in P-glycoprotein-mediated multidrug resistance. Crit Rev Clin Lab Sci (1998) 0.79
Phase II trial of high-dose recombinant leukocyte alpha-2 interferon for metastatic colorectal cancer without previous systemic treatment. Cancer Treat Rep (1985) 0.79
The development and purification of a bispecific antibody for lymphokine-activated killer cell targeting against the rat colon carcinoma CC531. Cancer Immunol Immunother (1993) 0.79
Effects of recombinant tumour necrosis factor (rTNF-alpha) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF-alpha administration in isolated limb perfusions in cancer patients. Eur J Clin Invest (1993) 0.79
In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. Br J Cancer (1999) 0.79
Bispecific antibodies in cancer therapy, from the laboratory to the clinic. J Immunother (1999) 0.79
Characterization of three new membrane structures on rat NK cells which are involved in activation of the lytic machinery. Immunobiology (1997) 0.78
The role of MHC class I expression in rat NK cell-mediated lysis of syngeneic tumor cells and virus-infected cells. Immunobiology (1996) 0.78
Characteristics of tumor infiltration by adoptively transferred and endogenous natural-killer cells in a syngeneic rat model: implications for the mechanism behind anti-tumor responses. Int J Cancer (1998) 0.78
31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion. NMR Biomed (1995) 0.78
Results of regional isolated perfusion for locally inoperable melanoma of the limbs. Melanoma Res (1994) 0.78
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma. Br J Cancer (1996) 0.78
Isolated limb perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalan. Arch Surg (1996) 0.78
Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol (1996) 0.78
Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients. Cancer Immunol Immunother (1997) 0.78
Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour. J Cancer Res Clin Oncol (1997) 0.78
Therapeutic lymphadenectomy in melanomas of the head and neck. Head Neck (1993) 0.78
In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour. J Cancer Res Clin Oncol (1993) 0.77
Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats. Anticancer Res (2000) 0.77
Interferon-alpha induced Raynaud's syndrome. Ann Oncol (2000) 0.77
The development of a bi-specific anti-CD161A x anti-tumor antibody for rat NK cell targeting. Immunobiology (1999) 0.77
The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat. J Cancer Res Clin Oncol (1994) 0.77
Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells. J Biol Response Mod (1987) 0.77
Electron microscopic observations on the accumulation of large granular lymphocytes (pit cells) and Kupffer cells in the liver of rats treated with continuous infusion of interleukin-2. Hepatology (1990) 0.77
Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas. Semin Surg Oncol (1998) 0.77